William Blair Issues Positive Forecast for TMDX Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) – Stock analysts at William Blair upped their Q3 2026 earnings estimates for shares of TransMedics Group in a research report issued to clients and investors on Thursday, October 23rd. William Blair analyst R. Daniels now forecasts that the company will earn $0.65 per share for the quarter, up from their previous estimate of $0.64. The consensus estimate for TransMedics Group’s current full-year earnings is $1.00 per share.

Several other analysts have also recently weighed in on TMDX. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective on the stock. Morgan Stanley increased their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Canaccord Genuity Group reiterated a “buy” rating and set a $142.00 target price on shares of TransMedics Group in a report on Tuesday, October 14th. Finally, Jefferies Financial Group started coverage on shares of TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $130.73.

TransMedics Group Stock Down 2.1%

Shares of NASDAQ TMDX opened at $129.71 on Monday. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $145.50. The stock has a market cap of $4.42 billion, a PE ratio of 67.21 and a beta of 2.08. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a 50-day moving average of $116.22 and a 200 day moving average of $116.61.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to analysts’ expectations of $146.64 million. During the same quarter in the prior year, the company earned $0.35 EPS. TransMedics Group’s revenue was up 37.7% compared to the same quarter last year.

Institutional Trading of TransMedics Group

A number of large investors have recently bought and sold shares of the business. Amalgamated Bank boosted its stake in TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock worth $1,285,000 after purchasing an additional 80 shares during the period. Canada Pension Plan Investment Board boosted its holdings in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in TransMedics Group by 24.5% during the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after buying an additional 108 shares in the last quarter. CWM LLC raised its position in TransMedics Group by 18.5% during the third quarter. CWM LLC now owns 897 shares of the company’s stock worth $101,000 after acquiring an additional 140 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in TransMedics Group by 4.4% during the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company’s stock worth $455,000 after acquiring an additional 142 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.